Physical and chemical stability of Taxotere (docetaxel) one-vial (20 mg/ml) infusion solution following refrigerated storage

Hart, M.; Acott, S.
January 2010
Ecancermedicalscience;2010, Vol. 4, p1
Academic Journal
A one-vial formulation of the chemotherapy agent Taxotere® (docetaxel) is likely to be commercially available in some countries in 2010. Through control of two significant potential risk factors for crystallization—intervention into the infusion bag (by using a one-step technique) and temperature (by use of refrigerated storage)—it was postulated that the risk of precipitation would be reduced and the storage time of Taxotere® increased using the one-vial formulation versus the two-vial formulation. Furthermore, improved convenience and flexibility were anticipated as a result of the easier and quicker preparation associated with the one-vial formulation versus the twovial formulation. The results of the physicochemical stability study presented here indicate that the one-vial formulation is indeed associated with reduced risk of precipitation of docetaxel. Moreover, refrigerated storage has been shown to extend the physical and chemical stability for up to seven days, versus 4 h for the currently approved two-vial formulation and 6 h for the one-vial formulation stored at room temperature. However, only physical and chemical stability have been assessed in this study.


Related Articles


    Because of recent CMS rulings regarding the reimbursement of chemotherapy administration in the physician offices, an increasing number of patients are being treated in hospital-based outpatient infusion centers. This transition to the hospital setting often finds the patient routed to many...

  • Home Healthcare Medical Devices: Infusion Therapy.  // Home Healthcare Medical Devices: Infusion Therapy;2004, p1 

    The article offers information on how to safely use of infusion pump. It is important to read the instructions on the proper use of an infusion pump. The most common problems with a infusion pump include over- or under-infusion, wrong programming and wrong prescription. The ways of managing...

  • Intrathecal drug therapy using the Codman Model 3000 Constant Flow Implantable Infusion Pumps: experience with 17 cases. Ethans, K. D.; Schryvers, O. I.; Nance, P. W.; Casey, A. R. // Spinal Cord;Apr2005, Vol. 43 Issue 4, p214 

    OBJECTIVES::The objective of this study was to evaluate the accuracy, reliability, safety, and efficacy of the Codman Model 3000 Constant Flow Implantable Infusion Pump for intrathecal baclofen delivery as a therapeutic option for the treatment of severe spasticity. The distinctive features of...

  • System infuses multiple IVs.  // Design News;4/23/90, Vol. 46 Issue 8, p38 

    The article introduces MiniMed III multiple-channel infusion system from MiniMed Technologies. It infuses multiple drugs, functions with all known types of IV drug therapy, and minimizes demands placed on medical personnel. The modular design also permits each channel to operate independently.

  • News Briefs.  // American Journal of Health-System Pharmacy;5/1/2012, Vol. 69 Issue 9, p737 

    The article offers news brief including FDA's approval to the Prometra programmable infusion pump system, Susan Goodin, associate director of clinical trials and therapeutics receiving the 2012 Award of Excellence from the Hematology/ Oncology Pharmacy Association and Daniel A. Zlott receiving...

  • infusion pump.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1194 

    A reference entry for "infusion pump" which refers to a pump employed to provide fluids into an artery, vein, or enteral tube is presented.

  • Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. Paul R. Ingram; David C. Lye; Paul A. Tambyah; Wei P. Goh; Vincent H. Tam; Dale A. Fisher // Journal of Antimicrobial Chemotherapy (JAC);Jul2008, Vol. 62 Issue 1, p168 

    Objectives Continuous vancomycin infusion is increasingly used for outpatient management of infections, but the relationship between vancomycin and nephrotoxicity is controversial. We investigated the risk factors associated with nephrotoxicity in this setting. Methods A retrospective cohort...

  • The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.  // Inflammatory Bowel Disease Monitor;2014, Vol. 14 Issue 2, p57 

    Antibodies to infliximab (ATI) are associated with low infliximab levels, infusion reactions and, in most studies, reduced treatment efficacy [1-3]. The relationship between the development of ATI and clinical response to infliximab is complex with some patients continuing to achieve a response...

  • Insulin Therapy in Pediatric Patients with Type I Diabetes: Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections. Nahata, Leena // Clinical Pediatrics;Jul/Aug2006, Vol. 45 Issue 6, p503 

    The goal of this article was to review studies comparing continuous subcutaneous insulin infusion (CSII) to multiple daily insulin injections (MDIs) in children and adolescents with type I diabetes on five parameters: glycemic control, adverse events, required insulin dosage, weight gain, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics